998 resultados para 204-1251F
Resumo:
Kirje 21.10.1964
Resumo:
Kirje
Resumo:
The Technology Governance Board (TGB), established pursuant to Iowa Code Section 8A.204, developed and published this strategic information technology plan in December 2006. This plan contains the TGB's vision, mission, goals, and strategies that will lead the executive branch to an information technology infrastructure and policies that will enhance and unify the technology infrastructure to support business operations for electronic government, consistent with the vision of providing sustained support for “extraordinary customer service”.
Resumo:
Kirje 7.7.1932
Resumo:
A Organização Mundial da Saúde definiu Sistema de Informação em Saúde (SIS) como um mecanismo de colecta, processamento, análise e transmissão da informação necessária para se planear, organizar e avaliar os serviços da saúde. Um sistema de informação sanitária é definido, também, como um conjunto de componentes e procedimentos inter-relacionados, organizados com o objectivo de criar informação sanitária e com capacidade para monitorizar o estado de saúde e os serviços de saúde de uma nação, por forma a melhorar os cuidados de saúde pública, a liderança e as decisões de gestão a todos os níveis.
Resumo:
SVUL:n ja TUL:n yhteistoimintaa. - Urho Kekkosen lausunto
Resumo:
This Technology Governance Board Annual Report provides information o the total annual executive branch information technology expenditures (hardware, software, and personnel) and estimates for the amount of technology spending to be requested for the succeeding fiscal year. The report contains a projection of technology cost savings, an accounting of the level of technology cost savings for the current fiscal year, and a comparison of the level of technology cost savings for the current fiscal year with that of the previous fiscal year. This report was produced in compliance with Iowa Code §8A.204(3a) and was submitted to the Governor, the Department of Management, and the General Assembly on January 8, 2007.
Resumo:
Temozolomide (Temodal, Temodar), an imidazol derivative, is a second-generation alkylating agent. The orally available prodrug with the capacity of crossing the blood-brain barrier received accelerated US FDA approval in 1999. Three pivotal Phase II trials showed modest activity in the treatment of recurrent anaplastic astrocytoma glioblastoma. In 2005, the FDA and the European Agency for the Evaluation of Medicinal Products approved temozolomide for use in newly diagnosed glioblastoma, in conjunction with radiotherapy, based on an European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada Phase III trial. The adverse events associated with temozolomide are mild-to-moderate and generally predictable; the most serious are noncumulative and reversible myelosuppression and, in particular, thrombocytopenia, which occurs in less than 5% of patients. Continuous temozolomide administration is associated with profound CD4-selective lymphocytopenia. Molecular studies have suggested that the benefit of temozolomide chemotherapy is restricted to patients whose tumors have a methylated methylguanine methyltransferase gene promotor and are thus unable to repair some of the chemotherapy-induced DNA damage. Temozolomide is under investigation for other disease entities, in particular lower-grade glioma, brain metastases and melanoma.
Resumo:
La Bible s’ouvre par deux compositions poétiques d’Alcuin qui encadrent l’Épître de saint Jérôme à Paulinus, « Frater Ambrosius... » (ff. 1-2r : Monumenta Germaniae Historica, Poetae latinae, I, 1, p. 287, LXVIII-LXX, v. 1-200 ; ff. 4r-v : Monumenta Germaniae Historica, Poetae latinae, I, 1, p. 283-284, LXV, I-III). La fin manque: la Bible s'interrompt à la fin de l'Epître de saint Paul aux Colossiens.